الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 118 |  |  |
| | | from | 118 | | |
Abstract
Viral infection or reactivation is an important source of morbidity in HSCT recipients, particularly after allo-HSCT. HHV-6 is part of the β-herpesvirus subfamily. HHV-6 has been classified into two discrete species: HHV-6A and HHV-6B. HHV-6B is a ubiquitous virus which infects greater than 90% of humans within the first 2 years of life. It is widely accepted that HHV-6B is the primary cause of exanthem subitum (roseola infantum or sixth disease) in children, whereafter it can establish latency. Reactivation of latent HHV-6 may occur especially under immunosuppressive conditions. HHV-6 reactivation in HSCT recipients range from being asymptomatic to being linked with fever, skin rash, pneumonitis, myelosuppression, delayed engraftment, CMV reactivation, life threatening conditions as encephalitis and aGVHD. PCR has become the pillar to detect HHV-6 reactivation, meanwhile, it’s important to interpret the results in the settings of clinical disease. It is still uncertain if antiviral prophylaxis would be of value to high-risk patients, and also treatment regimen after HSCT if HHV-6 reactivation has been identified.
This study aimd to determine the HHV-6 serostatus and incidence of HHV-6 reactivation among allo and auto-HSCT recipients. Also, correlate potentially attributed clinical manifestations to HHV-6 DNA plasma levels among the same patients.